Smith Howard S
Department of Anesthesiology, Albany Medical College, Albany, NY 12208, USA.
Pain Physician. 2008 Mar;11(2 Suppl):S121-32.
Opioids are broad-spectrum analgesics with potent pain-relieving qualities but also with potential adverse effects related to both short-term and long-term therapy. Researchers have attempted to alter existing opioid analgesics, utilize different routes/formulations, or combine opioid analgesics with other compounds in efforts to improve analgesia while minimizing adverse effects. Exogenous opioids, administered in efforts to achieve analgesia, work by mimicking the actions of endogenous opioids. Endogenous opioids and their receptors are located in the brain (supraspinal areas), spinal cord, and periphery. Although opioids and opioid receptors in the brain and spinal cord have received much attention over many years, peripheral endogenous opioid analgesic systems have only been extensively studied during the past decade. It has been known since 1990 that following injection into the rodent hindpaw, D-Ala(2),N-Me-Phe(4), Gly(5)-ol-enkephalin (DAMGO) [a muopioid receptor agonist] probably exerts its antinociceptive effects locally, since the doses administered are too low to have an effect in the central nervous system (CNS). This notion has been supported by the observation that the quaternary compound morphine methyliodide, which does not as readily cross the bloodbrain barrier and enter the CNS, produced antinociception following intradermal administration into the hindpaw, but not when the same dose was administered systemically (subcutaneously at a distant site). With a growing appreciation of peripheral endogenous opioids, peripheral endogenous opioid receptors, and peripheral endogenous opioid analgesic systems, investigators began growing hopeful that it may be possible to achieve adequate analgesics while avoiding unwanted central untoward adverse effects (e.g. respiratory depression, somnolence, addiction). Peripherally-acting opioids, which capitalize on peripheral endogenous opioid analgesic systems, may be one potential future strategy which may be utilized in efforts to achieve potent analgesia with minimal side effects.
阿片类药物是具有强效止痛特性的广谱镇痛药,但短期和长期治疗都有潜在的不良反应。研究人员试图改变现有的阿片类镇痛药,采用不同的给药途径/剂型,或将阿片类镇痛药与其他化合物联合使用,以提高镇痛效果并尽量减少不良反应。为实现镇痛而给予的外源性阿片类药物,其作用机制是模仿内源性阿片类药物的作用。内源性阿片类药物及其受体位于大脑(脊髓以上区域)、脊髓和外周。尽管多年来大脑和脊髓中的阿片类药物及阿片类受体备受关注,但外周内源性阿片类镇痛系统在过去十年才得到广泛研究。自1990年以来就已知道,将D-Ala(2),N-Me-Phe(4),Gly(5)-ol-脑啡肽(DAMGO,一种μ阿片受体激动剂)注射到啮齿动物后爪后,它可能在局部发挥其抗伤害感受作用,因为给药剂量太低,无法在中枢神经系统(CNS)产生作用。这一观点得到了以下观察结果的支持:季铵化合物甲基碘化吗啡不易穿过血脑屏障进入中枢神经系统,皮内注射到后爪后可产生抗伤害感受作用,但全身给药(在远处皮下注射相同剂量)时则不会。随着对外周内源性阿片类药物、外周内源性阿片类受体和外周内源性阿片类镇痛系统的认识不断增加,研究人员开始抱有希望,即有可能在避免不必要的中枢不良副作用(如呼吸抑制、嗜睡、成瘾)的同时实现充分镇痛。利用外周内源性阿片类镇痛系统的外周作用阿片类药物,可能是未来一种潜在的策略,可用于在尽量减少副作用的情况下实现强效镇痛。